Who
David Domzalski
President and CEO
Company insider
Files Form 4 as: President and CEO, VYNE Therapeutics; CEO, Foamix Pharmaceuticals.
In numbers
- Trades disclosed
- 105
- Buys
- 1
- Sells
- 12
- Bought
- $104K
- Sold
- $114K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 1 Jan 2018
- Last trade
- 23 Jul 2026
- Last filed
- 24 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jul 2026filed 24 Jul 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $71K79,391 at $0.8976 | filing |
| 23 Jul 2026filed 24 Jul 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $71K79,391 at $0.90 | filing |
| 30 Jun 2026filed 2 Jul 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $7,94812,214 at $0.6507 | filing |
| 30 Jun 2026filed 2 Jul 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $7,93912,214 at $0.65 | filing |
| 29 May 2026filed 2 Jun 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code A | $9,54530,791 at $0.31 | filing |
| 29 May 2026filed 2 Jun 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code A | $9,54530,791 at $0.31 | filing |
| 31 Mar 2026filed 2 Apr 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $8,50414,232 at $0.5975 | filing |
| 31 Mar 2026filed 2 Apr 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $8,53914,232 at $0.60 | filing |
| 31 Dec 2025filed 5 Jan 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $7,35812,684 at $0.5801 | filing |
| 31 Dec 2025filed 5 Jan 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $7,35712,684 at $0.58 | filing |
| 30 Sep 2025filed 2 Oct 2025 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $4,31012,676 at $0.34 | filing |
| 30 Jun 2025filed 2 Jul 2025 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $21K12,676 at $1.65 | filing |
| 2 Jun 2025filed 3 Jun 2025 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code A | $7,0328,681 at $0.81 | filing |
| 31 Mar 2025filed 2 Apr 2025 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $48K30,498 at $1.58 | filing |
| 21 Jan 2025filed 23 Jan 2025 | VYNE Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —730,000 at $0.00 | filing |
| 31 Dec 2024filed 2 Jan 2025 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $82K24,536 at $3.35 | filing |
| 30 Nov 2024filed 3 Dec 2024 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code A | $8,1923,901 at $2.10 | filing |
| 30 Sep 2024filed 2 Oct 2024 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,288685 at $1.88 | filing |
| 1 Jul 2024filed 3 Jul 2024 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,795935 at $1.92 | filing |
| 31 May 2024filed 4 Jun 2024 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code A | $9,5674,429 at $2.16 | filing |
News
No headline names them, or the companies they trade most, lately.